Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

14.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
14.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

Burden and Predictors of 30- and 90-Day Readmission in Patients With Aortic Dissection: A Nationwide Retrospective Analysis.

Cardiology in review·2026
Same author

Anti-Jka-mediated delayed hemolytic transfusion reaction mimicking warm autoimmune hemolytic anemia in a multiparous woman: a case report.

Annals of medicine and surgery (2012)·2026
Same author

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models.

iScience·2026
Same author

Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models.

Digital discovery·2026

Related Experiment Video

Updated: May 3, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K

Ibrutinib and indolent B-cell lymphomas.

Akintunde Akinleye1, Muhammad Furqan2, Oluwaseyi Adekunle3

  • 1Division of Hematology and Oncology, Department of Medicine, New York Medical College, Valhalla, NY; Department of Medicine, Richmond University Medical Center, Staten Island, NY.

Clinical Lymphoma, Myeloma & Leukemia
|January 22, 2014
PubMed
Summary

Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, shows promise for treating indolent B-cell lymphomas. This targeted therapy offers improved survival rates for patients with relapsed or refractory lymphomas.

Keywords:
Bruton's tyrosine kinaseChronic lymphocytic leukemia/small lymphocytic lymphomaFollicular lymphomaMantle cell lymphomaNon-Hodgkin lymphoma

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.0K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Related Experiment Videos

Last Updated: May 3, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.0K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Indolent B-cell lymphomas often resist complete remission and relapse after treatment.
  • Current immunochemotherapy improves disease control but not survival.
  • Novel targeted agents are needed for these hematological malignancies.

Purpose of the Study:

  • To review the achievements of ibrutinib in treating indolent B-cell lymphoid malignancies.
  • To highlight the emerging role of Bruton's tyrosine kinase (BTK) inhibitors.

Main Methods:

  • Review of early-phase and phase III clinical studies of ibrutinib.
  • Focus on studies involving patients with indolent B-cell lymphomas.
  • Analysis of target inhibition, tumor response, and survival data.

Main Results:

  • Ibrutinib demonstrates effective BTK inhibition and increased tumor response rates.
  • Significant improvements in survival have been observed, particularly in indolent B-cell lymphomas.
  • Ibrutinib received "breakthrough therapy" designation for mantle cell lymphoma and Waldenström macroglobulinemia.

Conclusions:

  • Ibrutinib is a promising novel agent for indolent B-cell lymphomas.
  • Targeted therapy with ibrutinib offers a new avenue for improving patient survival.
  • Further research and clinical application of ibrutinib are warranted.